Cost-Effectiveness of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Therapy in Older Patients with Myocardial Infarction
- 16 May 2000
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 132 (10) , 780-787
- https://doi.org/10.7326/0003-4819-132-10-200005160-00003
Abstract
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy has proven efficacy in reducing the rate of coronary and cerebrovascular events in patients 75 years of age or younger with a history of myocardial infarction. However, in patients older than 75 years of age, the efficacy and potential cost-effectiveness of statins are unknown. To estimate the incremental cost-effectiveness of statin therapy compared with usual care in patients 75 to 84 years of age with previous myocardial infarction. Cost-effectiveness analysis. Published data from cohort studies. Patients 75 to 84 years of age with a history of myocardial infarction. Lifetime. Societal. Statin therapy. Life expectancy, quality-adjusted life expectancy, and incremental cost-effectiveness. The incremental cost-effectiveness of statin therapy compared with usual care in patients 75 to 84 years of age with previous myocardial infarction was $18 800 per quality-adjusted life-year (QALY). On the basis of a probabilistic sensitivity analysis, there is a 75% chance that statin therapy costs less than $39 800 per QALY compared with usual care. If the cost of statin therapy and efficacy of statin therapy at reducing myocardial infarction were set to their most favorable values, statin therapy cost $5400 per QALY; if cost and efficacy were set to their least favorable values, statin therapy cost $97 800 per QALY. The cost-effectiveness ratios of statin therapy in older patients with previous myocardial infarction are reasonable under a wide variety of assumptions about drug efficacy, drug cost, and rates of cardiac and cerebrovascular events. Pending results of randomized, controlled trials of secondary prevention in patients in this age group, statin therapy seems to be as cost-effective as many routinely accepted medical interventions in this setting.Keywords
This publication has 34 references indexed in Scilit:
- The design of a prospective study of pravastatin in the elderly at risk (PROSPER)The American Journal of Cardiology, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) TrialAnnals of Internal Medicine, 1998
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- Cholesterol-Lowering Therapy in Women and Elderly Patients With Myocardial Infarction or Angina PectorisCirculation, 1997
- The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatinBMJ, 1997
- Cost Effectiveness of Simvastatin Treatment to Lower Cholesterol Levels in Patients with Coronary Heart DiseaseNew England Journal of Medicine, 1997
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)American Journal of Hypertension, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995